Category: Clinical Trials

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th – 30th June 2022) which attract more than 300 representatives from Korea’s top biopharmas, vaccine manufacturers, and biologics companies.

Novotech Country Managing Director Sanghee Kim said the Korea team was extremely pleased to receive this award in recognition of the clinical excellence provided to clients in the biologics sector.

Novotech Vice President Global Head Clinical Services Yooni Kim also said: “Novotech’s Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.”

Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, New Zealand, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Novotech CEO Dr. John Moller said: “The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest-growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms have accelerated approval processes. The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive a seamless service, with a unified approach to systems and SOPs,” Moller said.

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was awarded a prestigious Clinical Leader and Life Science Leader CRO Leadership Award for exceeding customer expectations, at Drug Information Association 2022 (DIA 2022).

Novotech CEO Dr. John Moller said the company was extremely pleased to receive this award for the second consecutive year. “Receiving this recognition from our clients is incredibly important to us and is an endorsement of our service delivery model that is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasises problem solving, ownership and flexibility, and our investments in data and technology ensure clients have real time access to trial performance.”

Book a meeting with one of the Novotech experts at DIA here. https://novotech-cro.com/contact

Clinical Leader and Life Science Leader working with Industry Standard Research (ISR), selected Novotech for the CRO Leadership Award.

According to the CRO Leadership Award research team: “The awards are based on customer feedback. Winning CROs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. Primary market research by ISR Reports is the basis of the awards. Sponsors provide ratings of CROs based on recent outsourced projects. This experiential feedback is analyzed by sponsor company size to reveal leading CROs in different performance categories.”

Ed Miseta, Chief Editor for Clinical Leader said: “Selecting the right CRO can make or break your project. It can lead to a successful regulatory submission and approval or cost you a lot of time and effort on a failed study. That makes CRO selection a stressful decision for any clinical operations manager. Regardless of whether you are concerned about compatibility, capabilities, expertise, quality, or reliability. We believe our CRO Leadership Awards will help managers with their search process and hopefully help to connect them with the right contract partner. We are grateful to our colleagues at ISR Reports for conducting the research necessary to produce these awards. These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for the work ethic they exhibit in consistently meeting the needs of their drug development clients.”

Kevin Olson, CEO of Industry Standard Research said: “Industry Standard Research (IRS) continues to consider it an honor to provide the primary market research data for Life Science Leader and Clinical Leader’s CRO Leadership Awards. ISR’s stringent screening process ensures that only highly qualified industry decision-makers participate in our CRO benchmarking market research. This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enable users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.”

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Novotech CEO Dr. John Moller said Novotech’s Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions. “The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”

About Novotech Health Holdings Pte Ltd (“Novotech”)
Novotech is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, will have key executives from APAC and the US attend BIO 2022 for meetings with biotechs considering the Asia-Pacific region to expedite their clinical trials. #4907

Book a meeting with one of the Novotech experts at BIO here. https://novotech-cro.com/contact

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies. Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.

Novotech CEO Dr. John Moller said Novotech’s Asia-Pacific and US teams support cost effective expedited clinical research with world-class data, and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.

“The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes. The expansion into the US was a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.” Clients will receive a seamless service, with a unified approach to systems and SOPs,” Moller said.

According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, Over the last five years more than 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%). The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, lower cost of conducting studies, high-quality standards and the presence of top clinical sites.

* https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 3,700 clinical trials across a broad range of therapeutic areas. Novotech is well positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, is sponsoring the Endpoints ASCO22 “Accelerating clinical development in China and the US”.

Register here https://asco22.endpts.com/
TUESDAY, JUNE 7
11:00am – 11:45am ET (1:00 – 1:45 local time)
Novotech Booth at ASCO #14115

The virtual session will cover the latest on the clinical trial landscape and infrastructure in China and includes Novotech’s DCT partner, Obvio Health, on DCT strategies for patient-centric, oncology study design and execution.

According to the Endpoints ASCO session: “China and the US are the world’s largest oncology research destinations, and the clinical research bridge between them supports accelerated clinical development from early to late phase trials while ensuring the inclusion of MRCT data packages in future regulatory applications. With experienced clinical teams in both regions, Novotech will share real-world success strategies for biotechs undertaking global clinical development programs.”

The expert panel features:

• Jin Li, Professor of the Department of Oncology, Shanghai East Hospital
• Peter Luo, Co-Founder, Chief Executive Officer and Chairman, Adagene
• Vivian Gu, Head of CDR China CMO Novotech
• Nancy Snowden, Head of US Operations, Novotech
• Susan Dallabrida, CEO and Chairman SPRIM, ObvioHealth

Moderated by: Arsalan Arif, Publisher & Founder Endpoints News

China offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KLOs.

According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5*, over the past 5 years the growth of oncology trials (CAGR of 25%) in China outpaced other countries. This growth was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immuno-oncology, and leadership in cell therapy. China also recorded the largest number of new trials, followed by the US. In China, the number of new trials doubled during 2017-2021. Notably, China’s regulatory reforms have accelerated drug approval by reducing the overall review and process. In addition, over the last five years more 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).

The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical institutions acting as sites. Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients. Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.

NCGS was established in 1984 in South Carolina and has a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said: “This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”
“Clients will receive seamless service, with a unified approach to systems and SOPs,” Moller said. Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China. Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data. Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

* https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, has sponsored expert panels at the Pre-ASCO China Summit 2022 bringing together leaders in oncology drug development in China and the US. The Pre-ASCO series was watched by more than 20,000 people globally.

The Novotech sponsored Summit sessions are:

• Go/No Go Decisions Based on Early Phase Oncology Trials – Watch Here https://tinyurl.com/novotech-webinars
• Development and Regulatory Strategy for China & US – Watch Here https://tinyurl.com/novotech-whitepapers

China offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations and world-class KOLs.

• According to Global Data whitepaper: EVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://tinyurl.com/novotech-whitepapers
• Over the past 5 years, growth of oncology trials (CAGR of 25%) in China outpaced other countries.
• This growth was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immuno-oncology, and leadership in cell therapy
• China also recorded the largest number of new trials, followed by the US. In China, the number of new trials doubled during 2017-2021. Notably, China’s regulatory reforms have accelerated drug approval by reducing the overall review and process.
• In addition, over the last five years more 70,000 new clinical trials were registered in the APAC region, the US, and the EU5. The APAC region was the largest contributor, with more than 50% of the trials followed by the US (29%) and the EU5 (17%).
• The APAC region has become the preferred destination for conducting clinical trials due to its large patient population, ease of regulatory compliance, low cost of conducting studies, high-quality standards and the presence of top clinical sites.

Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.

NCGS was established in 1984 in South Carolina and has a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said:
“This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”

“Clients will receive seamless service, with a unified approach to systems and SOPs,” Moller said.

Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.

Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.

Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its CRO services to the US, is pleased to sponsor the Pre-ASCO China Summit 2022 event titled: Go/No Go Decisions Based on Early Phase Oncology Trials (‘The Summit’).

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:

• Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
• Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China

Event Date:

• China Time: 9:00-10:30 AM, Saturday, May 14, 2022
• US EST Time: 9:00-10:30 PM, Friday, May 13, 2022
• US PST Time: 6:00-7:30 PM, Friday, May 13, 202
• Language: English, with Chinese simultaneous translatio
• Venue: Live Zoom Webinar
• Moderator:
• Dr. Li Yan, CMO, Brii Biosciences; Managing Director, United States Chinese Anti-Cancer Association (USCACA)

The Summit will start with a presentation by Novotech’s Senior Medical Monitor Dr. Ramandeep Sharma titled: Approaches, Experiences, and considerations for early phase go/no go.

• Dr. Jin Li, Shanghai East Hospital
• Dr. Li Yan, CMO, Brii Biosciences; Managing Director, USCACA
• Dr. Ramandeep Sharma, Senior Medical Monitor, Novotech
• Dr. Vivian Gu, Head of Clinical Development & Regulatory, CMO, Novotech China
• Dr. Xiaoxia Yan, Highthink
• Dr. Jianmin Fang, Co-founder, CEO & CSO, RemeGen
• Dr. Joseph Eid, Chief Medical Officer, Hengrui
• Dr. Jon Wigginton, Senior Advisor and Chairman SAB, Cullinan Oncology; Former Head of Immuno-Oncology Early Clinical Development, BMS

Earlier this month, Novotech announced the acquisition of US CRO, NCGS as part of a US service expansion program for its global base of clients.

Novotech, which has a reputation for delivering full-service, high-quality expedited clinical trials in Asia-Pacific, can now offer its biotech clients clinical services in the US to support later phase global studies.

NCGS was established in 1984 in South Carolina with a biopharma client base. NCGS has a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said:
“This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.”

“Clients will receive seamless service, with a unified approach to systems and SOPs well developed,” Moller said.

Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.

With more than 2,000 highly experienced professionals, clients benefit from strong site and Key Opinion Leader relationships, deep regulatory expertise, and the ability to accelerate clinical trials across the Asia Pacific and in particular China.

Novotech recently announced a partnership and investment in tech firm Prospection to support accelerated clinical trials with healthcare data analytics using real-world data.

Novotech has also partnered with virtual research organisation ObvioHealth to expedite trials leveraging remote technologies. This patient-centric approach improves subject retention and allows sponsors to reach populations outside major cities for clinical trial participation.

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, Novotech and PPC. Novotech is a CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. It has been instrumental in the success of approximately 3,700 clinical trials across all trial phases and broad range of therapeutic areas. Novotech is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For more information visit https://novotech-cro.com/contact

Media Contact
David James
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427

Novotech, the leading Asia-Pacific biotech specialist CRO, has acquired US CRO NCGS as part of its expansion program, and can now offer its biotech clients clinical services in the US to support later phase global studies. NCGS, established in 1984 in South Carolina, is a privately held CRO with a biopharma client base and a workforce of about 300 professionals across the US.

Novotech CEO Dr. John Moller said “We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United States. The company’s growth is a real credit to the knowledge and expertise of founder Nancy Snowden and the exceptional team she has formed.

“This is a strategic move to provide US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive seamless service, with a unified approach to systems and SOPs well developed,” Moller said.

Nancy C.G. Snowden, founder and CEO of NCGS, said the company was excited about becoming part of Novotech operations globally and supporting Novotech’s clients with their US clinical programs. “We have a similar cultural fit and focus on excellence, so joining Novotech will be seamless for both ours and Novotech’s clients. Novotech and NCGS have a collaboration history of over a decade which will also support the seamless integration,” said Snowden.

“NCGS focuses on complex areas of clinical development; oncology, hematology, infectious disease, and CNS in both adult and pediatric populations. Our lean organizational structure and nimble operational model with highly tenured staff have been specifically designed to overcome the challenges inhibiting our industry today. We have the ability to pivot in real time as the needs of the trial evolve,” Sowden said.

Novotech serves biotechs globally, leveraging deep relationships built with hundreds of Asia-Pacific sites over the last 25 years. NCGS compliments this with a broad US site base and hundreds of investigators with relationships spanning nearly four decades.

Media Contact:
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
ASIA: +65 3159 3427

About Novotech Health Holdings
Novotech Health Holdings Pte. Ltd. (“Novotech”) is a leading Asia-Pacific biotech specialist CRO with integrated labs and phase I facilities providing drug development consulting and clinical development services. Novotech Holdings is well positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. For further information, visit https://novotech-cro.com/.

About NCGS
NCGS Incorporated, founded in 1984, is a full-service CRO that specializes in conducting and managing clinical trials. NCGS has supported the development of more than 70 approved pharma-biotech, diagnostic and device products with over 80 indications during its nearly four decades of operation. For more information, please visit https://www.ncgs.com/sponsors/.